LYFE Capital

Founded 2014
Founders Drake Yu James Zhao


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 29
Average round size
The average size of a deal this fund participated in
Portfolio companies 23
Rounds per year 4.14
Lead investments 5
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees 3
Stages of investment
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Biopharma

The venture was found in Asia in China. The main office of represented VC is situated in the Shanghai.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The fund is constantly included in less than 2 deals per year. Considering the real fund results, this VC is 2 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2018.

Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Ansun BioPharma, Burning Rock Biotech, Aohua The fund has exact preference in a number of founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. We can highlight the next thriving fund investment areas, such as Therapeutics, Biotechnology.

The current fund was established by Drake Yu, James Zhao.

The usual cause for the fund is to invest in rounds with 5 partakers. Despite the LYFE Capital, startups are often financed by Legend Star, Sequoia Capital China, Nest.Bio Ventures. The meaningful sponsors for the fund in investment in the same round are Sequoia Capital China, Legend Star, Viventures. In the next rounds fund is usually obtained by Sequoia Capital China, Lilly Asia Ventures, Legend Star.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Edge Medical Robotics

Health Care
$200M06 Nov 2021 Futian District, Guangdong Province, China

Sciwind Biosciences

Health Care
$69M11 Oct 2021 Shangcheng District, Zhejiang, China


$55M12 Jul 2021 Suzhou, Jiangsu, China


Health Care
Life Science
$154M14 Jun 2021 Taizhou, Jiangsu, China

Zhenyi Yiliao

Health Care
10 May 2021 Nantong, Jiangsu, China

Molecular Assemblies

Health Care
$11M15 Apr 2021 San Diego, California, United States

Abogen Biosciences

Life Science
$92M08 Apr 2021 Gusu District, Jiangsu, China


Health Care
Information Technology
Medical Device
Personal Health
$55M07 Apr 2021 Rishon Lezion, Center District, Israel

ImmuneOnco Biopharma

Health Care
24 Mar 2021 Shanghai, China
ABclonal Biotechnology Completes $93 Million Series C Financing

– ABclonal Biotechnology, a global life science tools and services provider, recently completed its $92.9 million Series C financing led by Sequoia Capital China and healthcare-focused investor LYFE Capital.
– Other new and existing shareholders, such as Sigma Square Capital, Kinghall Ventures, and Lucion Capital, participated in the new round.
– ABclonal Biotechnology, parent company of Massachusetts-based life science research and diagnostic reagents manufacturer, ABclonal Technology, will use the additional funding to accelerate the company’s research and development pipeline for in vitro diagnostic raw materials and rapidly expand production capabilities of its research reagent products and services.
– ABclonal is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development. This will be the company’s first step toward using the $92.

Sciwind Biosciences Secures US$37 Million Series B Financing

– Sciwind biosciences secured US$37m series B financing.
– The financing was led by LYFE Capital and joined by the existing investors, Legend Capital and Haibang Venture Capital.
– Sciwind focuses on research and development of innovative biologics in the therapeutic area of chronic metabolic and immunological diseases and has driven multiple projects into clinical trials.
– Two more IND applications are expected to be filed in 2021 including an oral formulation of a highly active GLP-1 analogue.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent LYFE Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: